Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

71.33
+0.33000.46%
Post-market: 72.991.66+2.33%19:59 EST
Volume:2.27M
Turnover:161.26M
Market Cap:1.45B
PE:-9.03
High:73.37
Open:70.48
Low:67.70
Close:71.00
52wk High:73.37
52wk Low:6.48
Shares:20.34M
Float Shares:17.59M
Volume Ratio:0.61
T/O Rate:12.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.8997
EPS(LYR):-8.6765
ROE:-180.24%
ROA:-27.97%
PB:17.05
PE(LYR):-8.22

Loading ...

Nektar Therapeutics Closes $460 Million Equity Offering

MT Newswires Live
·
Feb 14

BUZZ-U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln National

Reuters
·
Feb 13

BUZZ-Nektar Therapeutics eases after boosted $400 mln share sale

Reuters
·
Feb 12

BRIEF-Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public Offering

Reuters
·
Feb 12

Nektar Therapeutics - Shares Sold at $58.00 per Share

THOMSON REUTERS
·
Feb 12

BUZZ-Nektar extends surge after promising eczema drug data

Reuters
·
Feb 11

U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart

Reuters
·
Feb 11

Nektar Therapeutics : Btig Raises Target Price to $151 From $118

THOMSON REUTERS
·
Feb 11

Nektar Therapeutics Launches $300 Million Public Offering with Pre-Funded Warrants

Reuters
·
Feb 11

Nektar Therapeutics Announces Proposed Public Offering

THOMSON REUTERS
·
Feb 11

Nektar Therapeutics - Announces $300 Mln Public Offering

THOMSON REUTERS
·
Feb 11

Nektar Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Feb 11

Nektar price target raised to $151 from $118 at BTIG

TIPRANKS
·
Feb 11

Nektar upgraded to Outperform from Market Perform at William Blair

TIPRANKS
·
Feb 11

Nektar Therapeutics : William Blair Raises to Outperform Rating

THOMSON REUTERS
·
Feb 11

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog​, Ecolab

Reuters
·
Feb 10

Nektar Therapeutics : H.c. Wainwright Raises Target Price to $165 From $135

THOMSON REUTERS
·
Feb 10

Nektar Therapeutics Rises on Positive Dermatitis Drug Data

Dow Jones
·
Feb 10

BUZZ-Nektar rises as eczema drug shows year‑long benefit

Reuters
·
Feb 10

New Rezolve-Ad Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements With Both Monthly and Quarterly Dosing

THOMSON REUTERS
·
Feb 10